Search

Your search keyword '"Whyte, Gregory"' showing total 326 results
Start Over Author "Whyte, Gregory"
326 results on '"Whyte, Gregory"'

2. The Effects of Inhaled Terbutaline on 3-km Running Time-Trial Performance.

Author

Molphy, John, Dickinson, John W., Chester, Neil J., Loosemore, Mike, and Whyte, Gregory

Subjects
DRUG therapy for asthma, ATHLETIC ability, BODY weight, EXERCISE physiology, INFORMED consent (Medical law), LACTATES, RESPIRATORY diseases, STATURE, TREADMILLS, ERGOGENIC aids, RANDOMIZED controlled trials, LONG-distance running, VITAL capacity (Respiration), BLIND experiment, INHALATION administration, TERBUTALINE, ONE-way analysis of variance, THERAPEUTICS
Abstract

Terbutaline is a prohibited drug except for athletes with a therapeutic use exemption certificate; terbutaline's effects on endurance performance are relatively unknown. Purpose: To investigate the effects of 2 therapeutic (2 and 4 mg) inhaled doses of terbutaline on 3-km running time-trial performance. Methods: A total of 8 men (age 24.3 [2.4] y; weight 77.6 [8] kg; and height 179.5 [4.3] cm) and 8 women (age 22.4 [3] y; weight 58.6 [6] kg; and height 163 [9.2] cm) free from respiratory disease and illness provided written informed consent. Participants completed 3-km running time trials on a nonmotorized treadmill on 3 separate occasions following placebo and 2- and 4-mg inhaled terbutaline in a single-blind, repeated-measures design. Urine samples (15 min postexercise) were analyzed for terbutaline concentration. Data were analyzed using 1-way repeated-measures analysis of variance, and significance was set at P < .05 for all analyses. Results: No differences were observed for completion times (1103 [201] s, 1106 [195] s, 1098 [165] s; P = .913) for the placebo or 2- and 4-mg inhaled trials, respectively. Lactate values were higher (P = .02) after 4 mg terbutaline (10.7 [2.3] mmol⋅L-1) vs placebo (8.9 [1.8] mmol⋅L-1). Values of forced expiratory volume in the first second of expiration (FEV1) were greater after inhalation of 2 mg (5.08 [0.2]; P = .01) and 4 mg terbutaline (5.07 [0.2]; P = .02) compared with placebo (4.83 [0.5] L) postinhalalion. Urinary terbutaline concentrations were mean 306 (288) ng⋅mL-1 and 435 (410) ng⋅mL-1 (P = .2) and peak 956 ng⋅mL-1 and 1244 ng⋅mL-1 after 2 and 4 mg inhaled terbutaline, respectively. No differences were observed between the male and female participants. Conclusions: Therapeutic dosing of terbutaline does not lead to an improvement in 3-km running performance despite significantly increased FEV1. The findings suggest that athletes using inhaled terbutaline at high therapeutic doses to treat asthma will not gain an ergogenic advantage during 3-km running performance. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

13. Effects of anabolic steroid use on myocardial perfusion in body-builders: a quantitative cardiovascular magnetic resonance Study

Author

Ismail Tevfik F, Hsu Li-Yueh, Angell Peter J, Jabbour Andrew, Greve Anders M, Gonçalves Carla, Gulati Ankur, Hewins Benjamin, Smith Gillian, Wage Rick, Dahl Annette L, Roughton Michael, Whyte Gregory, George Keith, Pennell Dudley J, Arai Andrew E, and Prasad Sanjay K

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results